

Chimeric antigen receptor T-cell (CAR-T cell) publication spotlight: Our top recent peer-reviewed journal articles featuring Fortrea oncologists discussing CAR-T drug development



CAR-T cell therapies have represented a breakthrough technology in some forms of leukemia and lymphoma with additional indications, with six approved treatments, hundreds of assets in development and well over 2000 clinical trials.¹

Fortrea supports our sponsors with a dedicated team of 50+ oncologists who take a collaborative approach to research, which can result in co-authorship of peer reviewed journal articles based on projects we've supported. In addition, they have contributed to industry knowledge via articles about their own academic and collaborative work. We are proud that our oncology team contributes to the advancement of cancer research in this way. Some of our latest publications relating to CAR-T cell therapies include the following articles.

2025

Number	Authors, Title, Journal
2025.1	<p>Besliu C, Tanase AD, Rotaru I, Espinoza J, Vidal L, Poelman M, Juan M, de Larrea CF, Saini KS. The evolving landscape in multiple myeloma: From risk stratification to T cell-directed advanced therapies. <i>Cancers (Basel)</i>. February 2025. https://doi.org/10.3390/cancers17030525</p> <p>Summary: This paper explores the evolving treatment landscape of multiple myeloma, emphasizing the shift toward advanced T-cell-directed therapies. It reviews how modern risk-stratification tools, disease biology and therapeutic innovations are reshaping clinical decision-making. The authors highlight emerging modalities—such as bispecific antibodies, novel immunotherapies and cellular approaches—that are expanding options for patients with relapsed or refractory disease. Despite significant progress, challenges related to treatment sequencing, toxicity management and equitable access remain, underscoring the need for continued research and refined clinical strategies.</p>

2023

Number	Authors, Title, Journal
2023.1	<p>Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, Prakash Prasad C, Singh A, Bhat AA, Macha MA, Benali M, Saini KS, Previs RA, Saini D, Saha D, Dutta P, Rai Bhatnagar A, Darswal M, Shankar A, Singh M. CAR-T-cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond. <i>Vaccines</i>. November 2023. https://doi.org/10.3390/vaccines11111721</p> <p>Summary: Cell and gene therapy, and in particular CAR-T cell therapy, has shown remarkable results in CD19-positive haematological cancers. In this paper, we review the recent progress made in testing CAR-T cell therapy to target B-cell maturation antigen-expressing cells in multiple myeloma.</p>

2022

Number	Authors, Title, Journal
2022.1	<p>Saini KS, Svane IM, Juan M, Barlesi F, André F. Manufacture of adoptive cell therapies at academic cancer centers: Scientific, safety and regulatory challenges. <i>Annals of Oncology</i>. January 2022. https://doi.org/10.1016/j.annonc.2021.09.020</p> <p>Summary: In this invited editorial published in <i>Annals of Oncology</i>, Fortrea oncologists and ESMO key opinion leaders summarize regulatory and financial aspects of CAR-T therapies, and argue for their decentralized manufacture.</p>

References

1. Saez-Ibañez AR, Upadhyaya S, Partridge T, Winkelman D, Gorrea D, Campel J. The changing landscape of cancer cell therapies: Clinical trials and real-world data, *Nature Reviews Drug Discovery*. <https://www.nature.com/articles/d41573-024-00094-4>. May 2024.



See a full list of Fortrea oncology publications starting in 2020.

LEARN MORE at fortrea.com

